Understanding HCT/P Section 361 vs 351 Compliance

Understanding HCT/P Section 361 vs 351 compliance for biologic procurement hinges on whether a human tissue product is minimally manipulated and intended strictly for homologous use (Section 361) or requires FDA pre-market approval via an IND or BLA (Section 351). Sourcing non-compliant tissues exposes practices to severe regulatory liability, inventory loss, and operational disruption. Evaluating processing methods, donor screening documentation, and vendor registration files enables clinical administrators to maintain a fully compliant biologics supply chain.

The FDA Regulatory Framework: 21 CFR Part 1271

The Food and Drug Administration (FDA) regulates human tissues under Title 21 of the Code of Federal Regulations (CFR) Part 1271. This framework establishes two distinct regulatory pathways for manufacturers, distributors, and healthcare facilities purchasing biologics and cellular therapy products.

Navigating this framework requires understanding why a product falls under a specific classification. Misclassifying an HCT/P can expose a practice to severe regulatory enforcement, including warning letters, product seizures, and legal liability. Procurement teams must evaluate every incoming biological product against FDA criteria rather than relying solely on vendor marketing materials.

Section 361 HCT/Ps: Criteria and Scope

To qualify as a Section 361 HCT/P, a tissue product must meet all four conditions set forth in 21 CFR 1271.10(a):

1. Minimal Manipulation: The processing of the tissue does not alter its original relevant biological characteristics (for structural tissue) or relevant biological functions (for non-structural tissue).
2. Homologous Use: The product is intended to perform the same basic function or functions in the recipient as in the donor.
3. No Combination Products: The HCT/P is not combined with another drug, device, or article, except for water, crystalloids, or sterilizing, preserving, or storage agents.
4. Systemic Effect and Metabolic Activity Rules: Either the HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or, if it does, it is intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

When an HCT/P satisfies all four criteria, it is regulated solely under Section 361. The manufacturer is required to register with the FDA, list its tissue products, and follow Good Tissue Practices (cGTP), but it does not need to submit a pre-market approval application.

Section 351 Biological Products: High-Oversight Regulatory Route

If a product fails to meet even one of the Section 361 criteria, it automatically defaults to regulation as a drug, device, or biological product under Section 351 of the PHS Act and the Federal Food, Drug, and Cosmetic Act. Section 351 products require pre-market review and clearance, such as an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application for clinical trials.

Examples of products requiring Section 351 clearance include expanded stem cell populations, non-homologous tissue applications, chemically modified tissue matrices, and most cell-free secretome or exosome preparations distributed for systemic administration.

Clinical vs. Operational Perspectives on Procurement

For the Medical Director and Clinicians

From a clinical workflow perspective, using non-compliant biologics creates significant clinical governance exposure. Treating clinicians are responsible for ensuring that any tissue or cell product administered in the clinic is legally marketed for its intended use.

Clinicians must review the supplier's intended use statements. If a manufacturer claims a tissue graft accelerates nerve regeneration or cures systemic inflammation, but supplies the tissue under a Section 361 registration, a compliance mismatch exists. Section 361 products cannot claim specific therapeutic drug actions without BLA authorization. Clinicians must align patient consent forms, chart notes, and promotional messaging with the verified regulatory status of the product.

For the Practice Manager and Procurement Lead

For administrators responsible for sourcing, purchasing, and workflow, regulatory non-compliance presents direct financial and operational risk. Purchasing Section 351 products from non-registered or unapproved suppliers can lead to rapid product recalls, vendor shutdown, and potential reimbursement audits.

Practice managers evaluating suppliers should request comprehensive compliance packets before issuing purchase orders. Reviewing tissue bank registration status, certificate of analysis (COA) documents, and lot-specific donor screening records protects the practice's balance sheet and operational license. For practice management insight across different delivery models, consult our resources for regenerative medicine doctors.

Procurement Compliance Checklist

When evaluating any new tissue or biologic supplier, procurement staff should verify the following operational and regulatory checkpoints:

• FDA Registration Status: Verify the donor processing facility maintains an active, unexpired FDA Establishment Registration (Form FDA 3356).
• Regulatory Classification Confirmation: Confirm in writing whether the vendor supplies the product under Section 361 or Section 351. Request supporting documentation if the product is claimed as 361-exempt.
• Homologous Use Alignment: Review product labels and marketing materials to ensure the supplier does not market a 361 tissue for non-homologous indications or drug-like therapeutic outcomes.
• Minimal Manipulation Documentation: Ensure processing methods (e.g., micronization, enzymatic digestion, or cryopreservation) do not exceed FDA thresholds for minimal manipulation.
• Donor Screening & Testing Protocols: Validate that all tissue lots include infectious disease testing records compliant with 21 CFR 1271 Subpart C.
• Chain of Custody & Cold Chain Logistics: Verify continuous temperature tracking and validated shipping containers for all frozen or cryopreserved shipments.

Common Sourcing Pitfalls and Misconceptions

Many practices encounter compliance issues due to prevalent industry misconceptions:

• "FDA Registered" does not mean "FDA Approved": An establishment registration simply informs the FDA that a facility processes tissue. It is not an endorsement, approval, or validation of the product's safety or clinical efficacy.
• Exosome and Secretome Misclassification: Cell-free isolates, conditioning media, and extracellular vesicles generally do not meet the criteria for Section 361 HCT/Ps because they rely on cellular metabolic activity during manufacturing or involve extensive processing. Most require Section 351 IND/BLA pathways.
• Misinterpreting Homologous Use: Using an amniotic membrane intended for wound covering as an injectable for joint space lubrication or systemic anti-aging constitutes a non-homologous use under FDA guidance.

What This Means for Your Practice

To ensure uninterrupted clinic operations and protect your practice against compliance liabilities, administrative and clinical leadership should take concrete next actions:

1. Audit Existing Biologic Inventory: Audit every biologic, cellular, and tissue product in your inventory against the 361/351 criteria.
2. Establish Standard Procurement SOPs: Implement a mandatory vendor intake protocol requiring tissue bank registration documents, FDA Form 3356 copies, and COAs prior to purchasing.
3. Review Clinical Marketing & Patient Materials: Audit clinic websites, social media channels, and consent forms to ensure treatment descriptions accurately reflect the compliant classification of the products used.
4. Standardize Storage and Handling: Review clinic freezer facilities, temperature logs, and handling protocols to maintain complete regulatory compliance from receiving to patient delivery.

For additional answers regarding sourcing standard operational protocols, review our frequently asked questions.

Partnering for Compliant Biologic Sourcing

Navigating the complex regulatory landscape of cell and tissue products requires a trusted distribution partner committed to transparency, compliance, and clinical integrity. To learn more about how we assist medical practices with fully compliant product selection and regulatory education, visit our about page or contact our clinical consulting team today.